Research programme: anti-cancer therapeutics - Halozyme

Drug Profile

Research programme: anti-cancer therapeutics - Halozyme

Alternative Names: HTI-1511; PEG NME8058; PEG NME8062; PEG-ADA2; PEG-ADA2-E182T; PEG-ADA2-K374D; PEG-ADA2-R222Q-S265N; PEGylated adenosine deaminase 2

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Halozyme Therapeutics
  • Class Auristatins; Enzymes; Immunoconjugates
  • Mechanism of Action Adenosine deaminase stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Lung cancer; Pancreatic cancer
  • Discontinued Solid tumours

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 20 Feb 2018 Halozyme's PEG-ADA 2 is available for licensing as of 12 Apr 2018. http://www.halozyme.com
  • 20 Feb 2018 Discontinued - Preclinical development of HTI 1511 for Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top